Minna Rahnasto-Rilla

Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines

Rahnasto-Rilla, Minna; Puumalainen, Tatu; Karttunen, Vilma; Adla, Santosh Kumar; Lahtela-Kakkonen, Maija. 2024. Bioorganic and medicinal chemistry. 112:

SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors

Djokovic, Nemanja; Rahnasto-Rilla, Minna; Lougiakis, Nikolaos; Lahtela-Kakkonen, Maija; Nikolic, Katarina. 2023. Pharmaceuticals. 16:

Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics

Djokovic, Nemanja; Ruzic, Dusan; Rahnasto-Rilla, Minna; Srdic-Rajic, Tatjana; Lahtela-Kakkonen, Maija; Nikolic, Katarina. 2022. Journal of chemical information and modeling. 62: 2571-2585

Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines

Järvenpää, Joni; Rahnasto-Rilla, Minna; Lahtela-Kakkonen, Maija; Küblbeck, Jenni. 2022. Biomedicine and pharmacotherapy. 147:

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes

Raunio Hannu, Juvonen Risto O, Poso Antti, Lahtela-Kakkonen Maija, Rahnasto-Rilla Minna. 2016. Drug metabolism letters. 10: 56-64

Sirtuin 6 (SIRT6) Activity Assays

Rahnasto-Rilla Minna, Lahtela-Kakkonen Maija, Moaddel Ruin. Teoksessa: Sarkar Sibaji(toim.) , 2016. Histone Deacetylases : Methods and Protocols, Part II. s. 259-269. Springer

In Silico Prediction of the Site of Oxidation by Cytochrome P450 3A4 That Leads to the Formation of the Toxic Metabolites of Pyrrolizidine Alkaloids

Fashe Muluneh M, Juvonen Risto O, Petsalo Aleksanteri, Vepsäläinen Jouko, Pasanen Markku, Rahnasto-Rilla Minna. 2015. Chemical research in toxicology. 28: 702-710

N-Acylethanolamines Bind to SIRT6

Rahnasto-Rilla Minna, Kokkola Tarja, Jarho Elina, Lahtela-Kakkonen Maija, Moaddel Ruin. 2015. Chembiochem. 17 (2016): 77-81

Time-dependent inhibition of CYP2C19 by isoquinoline alkaloids: in vitro and in silico analysis

Salminen Kaisa A, Rahnasto-Rilla Minna, Vaananen Raija, Imming Peter, Meyer Achim, Horling Aline, Poso Antti, Laitinen Tuomo, Raunio Hannu, Lahtela-Kakkonen Maija. 2015. Drug metabolism and disposition. 43: 1891-1904

Identification of a New Reactive Metabolite of Pyrrolizidine Alkaloid Retrorsine: (3H-Pyrrolizin-7-yl)methanol

Fashe Muluneh M, Juvonen Risto O, Petsalo Aleksanteri, Rahnasto-Rilla Minna, Auriola Seppo, Soininen Pasi, Vepsäläinen Jouko, Pasanen Markku. 2014. Chemical research in toxicology. 27: 1950-1957

Quantitative insights for the design of substrate-based SIRT1 inhibitors

Kokkonen Piia, Mellini Paolo, Nyrhilä Olli, Rahnasto-Rilla Minna, Suuronen Tiina, Kiviranta Päivi, Huhtiniemi Tero, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2014. European journal of pharmaceutical sciences. 59: 12-19

Rational design of novel CYP2A6 inhibitors

Tani Niina, Juvonen Risto O, Raunio Hannu, Fashe Muluneh, Leppänen Jukka, Zhao Bin, Tyndale Rachel F, Rahnasto-Rilla Minna. 2014. Bioorganic and medicinal chemistry. 22: 6655-6664

Studying SIRT6 regulation using H3K56 based substrate and small molecules

Kokkonen Piia, Rahnasto-Rilla Minna, Mellini Paolo, Jarho Elina, Lahtela-Kakkonen Maija, Kokkola Tarja. 2014. European journal of pharmaceutical sciences. 63: 71-76

Vierasaineiden metabolia

Raunio Hannu, Pasanen Markku, Juvonen Risto, Rahnasto-Rilla Minna, Tani Niina, Hukkanen Kaisa, Huuskonen Pasi, Muluneh Fashe. 2014. Dosis. 30: 208

Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans

Tani Niina, Rahnasto-Rilla Minna, Wittekindt Carsten, Salminen Kaisa A, Ritvanen Anniina, Ollakka Riina, Koskiranta Jenna, Raunio Hannu, Juvonen Risto O. 2012. European journal of medicinal chemistry. 47: 270-277

CYP2A6: genetics, structure, regulation, and function

Raunio Hannu, Rahnasto-Rilla Minna. 2012. Drug metabolism and drug interactions. 27: 73-88

Comparison of Electrochemical and Biological Oxidation of Pyrrolizidine Alkaloid Retrorsine

Fashe Muluneh, Petsalo Aleksanteri, Juvonen Risto O, Rahnasto-Rilla Minna, Pasanen Markku, Auriola Seppo. 2012. Dosis

Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver

Abu-Bakar A'edah, Hakkola Jukka, Juvonen Risto, Rahnasto-Rilla Minna, Raunio Hannu, Lang Matti A. 2012. Current drug metabolism. 2013:14: 137-150

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site

Martikainen Laura E, Rahnasto-Rilla Minna, Neshybova Silvie, Lahtela-Kakkonen Maija, Raunio Hannu, Juvonen Risto O. 2012. European journal of pharmaceutical sciences. 47: 996-1005

Metabolism of bilirubin by human cytochrome P450 2A6

Abu-Bakar A'edah, Arthur Dionne M, Wikman Anna S, Rahnasto Minna, Juvonen Risto O, Vepsäläinen Jouko, Raunio Hannu, Ng Jack C, Lang Matti A. 2012. Toxicology and applied pharmacology. 261: 50-58

Peptides and Pseudopeptides as SIRT6 Inhibitors

Piia Kokkonen, Minna Rahnasto-Rilla, Päivi Kiviranta, Tero Huhtiniemi, Tuomo Laitinen, Antti Poso, Elina Jarho, Maija Lahtela-Kakkonen. 2012.

Peptides and pseudopeptides as SIRT6 deacetylation inhibitors

Kokkonen Piia, Rahnasto-Rilla Minna, Kiviranta Päivi H, Huhtiniemi Tero, Laitinen Tuomo, Poso Antti, Jarho Elina, Lahtela-Kakkonen Maija. 2012. Acs medicinal chemistry letters. 3: 969-974

Identification of novel CYP2A6 inhibitors by virtual screening

Rahnasto Minna K, Raunio Hannu A, Wittekindt Carsten, Salminen Kaisa A, Leppänen Jukka, Juvonen Risto O, Poso Antti, Lahtela-Kakkonen Maija K. 2011. Bioorganic and medicinal chemistry. 19: 7186-7193

Development of Inhibitors of the Human CYP2A6 Enzyme. in vitro and in silico Study

Rahnasto M. 2009. Kuopion yliopiston julkaisuja A. Farmaseuttiset tieteet

Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme-an in silico approach

Rahnasto M, Wittekindt C, Juvonen RO, Turpeinen M, Petsalo A, Pelkonen O, Poso A, Stahl G, Höltje H-D, Raunio H. 2008. Pharmacogenomics journal. 8: 328-338

Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo

Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO. 2008. Xenobiotica. 38: 34-47

New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis

Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H, Juvonen RO. 2007. British journal of pharmacology. 150: 932-942

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors

Korhonen LE, Rahnasto M, Mähönen N J, Wittekindt C, Poso A, Juvonen RO, Raunio H. 2005. Journal of medicinal chemistry. 48: 3808-3815

Quantitative structure - activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme

Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. 2005. Journal of medicinal chemistry. 48: 440-449

More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde

Rahnasto M, Raunio H, Poso A, Juvonen RO. 2003. Xenobiotica. 33: 529-539

Tarkenna hakuasi

Minna Rahnasto-Rilla

Tutkimusryhmät

Julkaisut

Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines

SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors

Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics

Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines

Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle

Quercetin based derivatives as sirtuin inhibitors

Natural polyphenols as sirtuin 6 modulators

The Identification of a SIRT6 Activator from Brown Algae Fucus distichus

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes

Sirtuin 6 (SIRT6) Activity Assays

In Silico Prediction of the Site of Oxidation by Cytochrome P450 3A4 That Leads to the Formation of the Toxic Metabolites of Pyrrolizidine Alkaloids

N-Acylethanolamines Bind to SIRT6

Time-dependent inhibition of CYP2C19 by isoquinoline alkaloids: in vitro and in silico analysis

Identification of a New Reactive Metabolite of Pyrrolizidine Alkaloid Retrorsine: (3H-Pyrrolizin-7-yl)methanol

Quantitative insights for the design of substrate-based SIRT1 inhibitors

Rational design of novel CYP2A6 inhibitors

Studying SIRT6 regulation using H3K56 based substrate and small molecules

Vierasaineiden metabolia

Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans

CYP2A6: genetics, structure, regulation, and function

Comparison of Electrochemical and Biological Oxidation of Pyrrolizidine Alkaloid Retrorsine

Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site

Metabolism of bilirubin by human cytochrome P450 2A6

Peptides and Pseudopeptides as SIRT6 Inhibitors

Peptides and pseudopeptides as SIRT6 deacetylation inhibitors

Identification of novel CYP2A6 inhibitors by virtual screening

Development of Inhibitors of the Human CYP2A6 Enzyme. in vitro and in silico Study

Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme-an in silico approach

Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo

New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors

Quantitative structure - activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme

More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde